Fig. 3

Small molecule inhibitors of histone deacetylase 6 (HDAC6) as anticancer strategy in inflammatory (IBC). a Normalized numbers of cells when cultures are treated with different concentrations of Ricolinostat for two doubling times. b Induction of apoptosis as measured by Annexin-V/7-AAD assay in cells shown in a. c Growth of IBC cells grown as xenograft models treated with Ricolinostat (50 mg/kg once daily for five days a week). Treating with paclitaxel (10 mg/kg/ twice a week) was also included for comparison of the anticancer response. The treatment regimen is graphically shown. Red arrows in each growth curve represent the initiation of the treatments. d Biochemical selectivity profiles of the second generation HDAC6 inhibitors (left table), their efficacy to induce accumulation of Ac-α-tubulin when IBC and non-IBC cells were treated at 2.5 μM for 16 hours (left panel), and as the impact that treating those cells for one doubling time had on cell number. In all panels asterisks indicate statistically significant differences (t test, p <0.05) for treatments based on HDAC6 inhibitors: n >=6 for both in vitro and in vivo treatments